KR102022575B1 - 탈유비퀴틴화 활성의 저해 방법 - Google Patents

탈유비퀴틴화 활성의 저해 방법 Download PDF

Info

Publication number
KR102022575B1
KR102022575B1 KR1020147012947A KR20147012947A KR102022575B1 KR 102022575 B1 KR102022575 B1 KR 102022575B1 KR 1020147012947 A KR1020147012947 A KR 1020147012947A KR 20147012947 A KR20147012947 A KR 20147012947A KR 102022575 B1 KR102022575 B1 KR 102022575B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
phenyl
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147012947A
Other languages
English (en)
Korean (ko)
Other versions
KR20140078742A (ko
Inventor
스티그 린데르
롤프 라르손
Original Assignee
비보룩스 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비보룩스 아베 filed Critical 비보룩스 아베
Publication of KR20140078742A publication Critical patent/KR20140078742A/ko
Application granted granted Critical
Publication of KR102022575B1 publication Critical patent/KR102022575B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147012947A 2011-10-19 2012-10-15 탈유비퀴틴화 활성의 저해 방법 Expired - Fee Related KR102022575B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1100776 2011-10-19
SE1100776-2 2011-10-19
SE1200303 2012-05-16
SE1200303-4 2012-05-16
PCT/SE2012/000158 WO2013058691A1 (en) 2011-10-19 2012-10-15 Method for inhibition of deubiquitinating activity

Publications (2)

Publication Number Publication Date
KR20140078742A KR20140078742A (ko) 2014-06-25
KR102022575B1 true KR102022575B1 (ko) 2019-09-18

Family

ID=48141165

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012947A Expired - Fee Related KR102022575B1 (ko) 2011-10-19 2012-10-15 탈유비퀴틴화 활성의 저해 방법

Country Status (21)

Country Link
US (1) US9221761B2 (https=)
EP (1) EP2780326B1 (https=)
JP (1) JP6165748B2 (https=)
KR (1) KR102022575B1 (https=)
CN (1) CN104271557B (https=)
AU (1) AU2012326682B2 (https=)
BR (1) BR112014009365B1 (https=)
CA (1) CA2852518C (https=)
CL (1) CL2014000998A1 (https=)
DK (1) DK2780326T3 (https=)
EA (1) EA026409B1 (https=)
ES (1) ES2713484T3 (https=)
HU (1) HUE041816T2 (https=)
IL (1) IL232118A (https=)
MX (1) MX345467B (https=)
MY (1) MY169330A (https=)
PL (1) PL2780326T3 (https=)
PT (1) PT2780326T (https=)
SG (1) SG11201401608PA (https=)
WO (1) WO2013058691A1 (https=)
ZA (1) ZA201403302B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401608PA (en) * 2011-10-19 2014-07-30 Vivolux Ab Method for inhibition of deubiquitinating activity
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CA2976741C (en) * 2015-03-30 2023-01-17 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
CN106146542A (zh) * 2015-04-23 2016-11-23 北京大学 姜黄素硼酸衍生物,其制备方法和应用
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
US10416163B2 (en) * 2016-02-26 2019-09-17 Regents Of The University Of Minnesota Method and treatment of recurring endometrial cancer with an inhibitor of USP14
WO2018140907A1 (en) * 2017-01-30 2018-08-02 Up Therapeutics Inc. Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CN111956804B (zh) * 2020-07-21 2022-01-07 广州医科大学 Otub1的抑制剂的新应用
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059613A1 (en) 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
WO2011005790A1 (en) 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664272B2 (en) * 1999-12-03 2003-12-16 Emory University Curcumin analogs with anti-tumor and anti-angiogenic properties
EP1572078A4 (en) * 2002-03-08 2006-08-09 Univ Emory NEW CURCUMINOID FACTOR VIIa CONSTRUCTS AS MEANS OF SUPPRESSING TUMOR GROWTH AND ANGIOGENESIS
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
SG11201401608PA (en) * 2011-10-19 2014-07-30 Vivolux Ab Method for inhibition of deubiquitinating activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059613A1 (en) 2005-11-22 2007-05-31 University Of Saskatchewan Antineoplastic compounds
WO2011005790A1 (en) 2009-07-06 2011-01-13 The Ohio State University Research Foundation Compositions and methods for inhibition of cancers

Also Published As

Publication number Publication date
WO2013058691A1 (en) 2013-04-25
ES2713484T3 (es) 2019-05-22
AU2012326682A1 (en) 2014-05-01
US20140228354A1 (en) 2014-08-14
EP2780326B1 (en) 2018-12-26
DK2780326T3 (en) 2019-03-04
MX345467B (es) 2017-02-01
MX2014004646A (es) 2014-08-01
KR20140078742A (ko) 2014-06-25
AU2012326682B2 (en) 2016-02-18
ZA201403302B (en) 2015-05-27
PT2780326T (pt) 2019-03-04
HUE041816T2 (hu) 2019-05-28
EP2780326A1 (en) 2014-09-24
MY169330A (en) 2019-03-21
US9221761B2 (en) 2015-12-29
IL232118A (en) 2016-06-30
CA2852518A1 (en) 2013-04-25
SG11201401608PA (en) 2014-07-30
BR112014009365B1 (pt) 2021-08-03
CN104271557A (zh) 2015-01-07
EA201490800A1 (ru) 2014-09-30
EA026409B1 (ru) 2017-04-28
BR112014009365A2 (pt) 2017-04-18
CL2014000998A1 (es) 2014-10-10
HK1203194A1 (en) 2015-10-23
NZ624019A (en) 2016-07-29
JP2014530852A (ja) 2014-11-20
CA2852518C (en) 2019-09-24
JP6165748B2 (ja) 2017-07-19
PL2780326T3 (pl) 2019-06-28
EP2780326A4 (en) 2015-04-22
CN104271557B (zh) 2017-12-05
IL232118A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
KR102022575B1 (ko) 탈유비퀴틴화 활성의 저해 방법
Zhang et al. Targeting p53-MDM2-MDMX loop for cancer therapy
US20050203063A1 (en) Proteasome pathway inhibitors and related methods
Zhang et al. Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development
Vu et al. Small-molecule inhibitors of the p53-MDM2 interaction
Sheng et al. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease
US9896420B2 (en) N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
Ugwu et al. Synthesis and structural activity relationship study of antitubercular carboxamides
Sosič et al. Cathepsin B inhibitors: Further exploration of the nitroxoline core
KR20150093695A (ko) Malt1의 소분자 억제제
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
Fu et al. Discovery of novel indole derivatives that inhibit NEDDylation and MAPK pathways against gastric cancer MGC803 cells
Xiong et al. Development of potent NEDD8-activating enzyme inhibitors bearing a pyrimidotriazole scaffold
Sharma et al. Enhancement of Chemotherapeutic Efficacy by Small Molecule Inhibition of NF-κ B and Checkpoint Kinases
Shan et al. Identification of a diketopiperazine‐based O‐GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition
KR100768021B1 (ko) 시스-2,4,5-트리아릴-이미다졸린
Clements et al. Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials
Xu et al. The development of small molecule inhibitors of glutaminyl cyclase and isoglutaminyl cyclase for Alzheimer's disease
SE1200735A1 (sv) Sätt att inhibera deubiqutineringsaktivitet
HK1203194B (en) Method for inhibition of deubiquitinating activity
CN111253371A (zh) 靶向cdk9的小分子调控剂、及其合成方法与应用
JP2008517065A (ja) Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法
NZ624019B2 (en) Method for inhibition of deubiquitinating activity
WO2025193649A1 (en) Use of a cbp/p300 degrader for the treatment of cancer
Mao et al. The ubiquitin-proteasomal system and blood cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220729

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230911

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230911